BIO-Europe® 2016: Promethera extends series C on interest from Asian investors

December 6, 2016
Dr. John Tchelingerian, CEO of Promethera Biosciences, talks to Scrip senior writer Lucie Ellis on the sidelines of the 2016 BIO-Europe partnering meeting about the company’s liver disease pipeline and series C financing. Promethera is a clinical stage pharmaceutical company developing innovative therapies for the treatment of liver diseases—its lead compound HepaStem is currently in Phase IIb for urea cycle disorders. The company also has a HepaStem/H2Stem preclinical program targeting fibrosis and NASH (non-alcoholic steatohepatitis).
Previous Video
BIO-Europe® 2016: AdAlta CEO on shark antibody technology
BIO-Europe® 2016: AdAlta CEO on shark antibody technology

AdAlta is developing a novel technology platform that engineers the key stability features of the antigen b...

Next Video
BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance
BIO-Europe® 2016: Deciphera CEO on tackling cancer drug resistance

Mike Ward, global director of content for Informa Pharma Intelligence, chats with Deciphera Pharmaceuticals...